ELAD

ELAD (Extracorporeal Liver Assist Device) is a bioartificial liver support system developed by Vital Therapies, Inc. It is an extracorporeal human allogeneic cellular therapy designed to support patients with liver failure. The system utilizes four hollow-fiber cartridges containing approximately 440 grams of human C3A cells, which are a clonal derivative of the HepG2 hepatoblastoma cell line. During treatment, the patient's plasma is circulated through the device, where the C3A cells perform essential metabolic and synthetic functions, such as protein synthesis (e.g., albumin, alpha-fetoprotein) and the metabolism of toxins, mimicking the activity of a healthy liver. The therapy was primarily investigated for acute-on-chronic hepatitis (AOCH) and severe alcoholic hepatitis (sAH) to provide a bridge to recovery or transplantation. However, development was halted in 2018 after the pivotal Phase 3 VTL-308 trial failed to meet its primary endpoint of improved overall survival.

Brand names

ELAD

Other names

Extracorporeal Liver Assist DeviceC3A cell therapyC-3A cell therapyC 3A cell therapyVTI-208VTI208VTI 208